April 3, 2026
Vanderbilt Center for Antibody Therapeutics signs agreement to develop anti-measles antibody treatment
“These antibodies hold significant promise to be used in people who are at risk of measles, but who cannot respond to the measles vaccine due to their weakened immune systems,” said James Crowe Jr., MD, whose research team isolated the human monoclonal antibodies.
By Bill Snyder